Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins.

Akache B, Deschatelets L, Harrison BA, Dudani R, Stark FC, Jia Y, Landi A, Law JLM, Logan M, Hockman D, Kundu J, Tyrrell DL, Krishnan L, Houghton M, McCluskie MJ.

Vaccines (Basel). 2019 Dec 3;7(4). pii: E204. doi: 10.3390/vaccines7040204.

2.

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma.

Stark FC, Agbayani G, Sandhu JK, Akache B, McPherson C, Deschatelets L, Dudani R, Hewitt M, Jia Y, Krishnan L, McCluskie MJ.

Biomedicines. 2019 Nov 23;7(4). pii: E91. doi: 10.3390/biomedicines7040091.

3.

Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.

Stark FC, Akache B, Ponce A, Dudani R, Deschatelets L, Jia Y, Sauvageau J, Williams D, Jamshidi MP, Agbayani G, Wachholz K, Harrison BA, Li X, Krishnan L, Chen W, McCluskie MJ.

Vaccine. 2019 Nov 8;37(47):7108-7116. doi: 10.1016/j.vaccine.2019.07.010. Epub 2019 Aug 2.

4.

A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations.

Jia Y, Akache B, Deschatelets L, Qian H, Dudani R, Harrison BA, Stark FC, Chandan V, Jamshidi MP, Krishnan L, McCluskie MJ.

Int J Pharm. 2019 Apr 20;561:187-196. doi: 10.1016/j.ijpharm.2019.02.041. Epub 2019 Mar 2.

PMID:
30836154
5.

Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.

Akache B, Stark FC, Jia Y, Deschatelets L, Dudani R, Harrison BA, Agbayani G, Williams D, Jamshidi MP, Krishnan L, McCluskie MJ.

PLoS One. 2018 Dec 4;13(12):e0208067. doi: 10.1371/journal.pone.0208067. eCollection 2018.

6.

Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.

Akache B, Stark FC, Iqbal U, Chen W, Jia Y, Krishnan L, McCluskie MJ.

Hum Vaccin Immunother. 2018 Jul 3;14(7):1746-1759. doi: 10.1080/21645515.2017.1423154. Epub 2018 Jan 30.

7.

An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.

Stark FC, Weeratna RD, Deschatelets L, Gurnani K, Dudani R, McCluskie MJ, Krishnan L.

Vaccines (Basel). 2017 Oct 26;5(4). pii: E38. doi: 10.3390/vaccines5040038.

9.

Lack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells.

Stark FC, Gurnani K, Sad S, Krishnan L.

PLoS One. 2012;7(2):e32211. doi: 10.1371/journal.pone.0032211. Epub 2012 Feb 16.

10.

Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.

Krishnan L, Deschatelets L, Stark FC, Gurnani K, Sprott GD.

Clin Dev Immunol. 2010;2010:578432. doi: 10.1155/2010/578432. Epub 2011 Jan 18.

11.

Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection.

Stark FC, Sad S, Krishnan L.

Cancer Res. 2009 May 15;69(10):4327-34. doi: 10.1158/0008-5472.CAN-08-3160. Epub 2009 May 12.

Supplemental Content

Loading ...
Support Center